Semaglutide's effect on the thyroid: what we know, what's still uncertain

Where the thyroid concern originated, and what regulators decided

When Novo Nordisk ran pre-clinical studies on GLP-1 receptor agonists, high-dose, long-duration experiments in rodents produced C-cell hyperplasia and medullary thyroid tumours. C-cells are the thyroid cells that produce calcitonin, and they carry GLP-1 receptors in rodents at a density that appears far higher than in human thyroid tissue. That biological difference is the core of why regulators drew a line between animal data and human risk.

The European Medicines Agency and the MHRA both reviewed this pre-clinical signal before authorising semaglutide. The STEP 1 trial, which followed 1,961 adults over 68 weeks, monitored calcitonin levels throughout and found no clinically meaningful rise in the semaglutide group compared with placebo, a finding consistent with the broader STEP programme published in the New England Journal of Medicine. Subsequent post-marketing surveillance across hundreds of thousands of patients has not produced a signal indicating that semaglutide causes thyroid cancer in humans. The NHS medicines page for semaglutide reflects this conclusion: the risk in people with normal thyroid history appears theoretical rather than demonstrated.

That said, regulators retained a contraindication for anyone with a personal or family history of medullary thyroid carcinoma or MEN2, a rare hereditary syndrome involving multiple endocrine glands. This is a hard stop in the prescribing rules, not a grey area to negotiate with your prescriber.

What this means for people with an existing thyroid condition

The contraindication above is specific: it covers MTC and MEN2. It does not extend to far more common thyroid conditions. People living with hypothyroidism managed on levothyroxine, or with autoimmune thyroiditis (Hashimoto's disease), are not automatically excluded from semaglutide, and our page on whether and how semaglutide affects the thyroid covers what the evidence says for those with existing thyroid conditions. A prescriber will want to know your thyroid history and whether your condition is stable and well-managed, but thyroid disease in itself is not a blanket bar.

One practical point worth knowing: semaglutide slows gastric emptying, and some evidence suggests this may slightly delay absorption of oral medicines taken in the morning, including levothyroxine. If your thyroid function tests have shifted since starting treatment, mentioning the timing of when you take your levothyroxine is worth raising with your GP or endocrinologist. It takes about a minute to check whether you are still leaving the recommended gap between the tablet and food or other medicines, which is a habit worth confirming at the start of any new weight-management treatment.

You can read more about how semaglutide interacts with other body systems in our overview of semaglutide's effects on the liver, which covers a separate but related set of questions that come up alongside thyroid concerns.

Symptoms to take seriously and who to contact

Because the MTC risk, while not established in humans, cannot be completely excluded, semaglutide's prescribing information asks patients and clinicians to stay alert to specific symptoms. These are: a new lump or swelling in the neck, hoarseness that is not explained by a cold or infection, difficulty swallowing, and persistent shortness of breath. If any of these appear during treatment, seek medical advice promptly, do not sit on it until your next routine appointment.

This caution sits alongside the general safety framework for GLP-1 medicines. The MHRA's Yellow Card scheme allows patients and clinicians to report suspected side effects, including any unexpected thyroid-related changes; those reports feed into ongoing post-marketing safety reviews and contribute to the evidence base over time.

For the subset of people who are uncertain whether their thyroid history affects their eligibility, the right starting point is a conversation with a GP or endocrinologist who knows their full medical record. Our page on Wegovy and thyroid cancer goes into the MTC and MEN2 contraindication in more detail if you want to understand the clinical reasoning further.

Where to go from here

If your thyroid history sits outside the MTC/MEN2 contraindication and you are wondering whether Wegovy could be suitable for your weight management, the next step is a clinical consultation. At nume, every consultation is read the same day by a GPhC-registered Independent Prescriber, not automated software, and your full medical history is part of that review. You can find more about how Wegovy works as a weight-management treatment, or explore the broader treatment options available if you are still weighing up the right route. Semaglutide's effect on other organ systems, such as the kidneys, is covered on our semaglutide and kidneys page for a fuller picture of what the clinical evidence shows.

Wegovy is a prescription-only medicine, and anyone who is pregnant or planning a pregnancy should be aware that our page on semaglutide's effects during pregnancy sets out the current guidance before starting or continuing treatment. A prescriber decides suitability based on your individual circumstances. Check your eligibility with our clinical team and get a same-day review of your consultation at no cost.